Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
NCT01539291
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
161
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
Idelalisib
Sponsor
Gilead Sciences